Back to today’s briefing

Story perspectives

Breakthroughs in Breast Cancer Treatments Unveiled at SABCS 2024

1/12/2025

49 10

Summary

Story summary

At SABCS 2024, Dr. Avan J. Armaghani unveiled promising advancements in treating hormone receptor-positive, HER2-negative metastatic breast cancer. The EMBER-3 study showcased the powerful combination of imlunestrant and abemaciclib, while the OlympiA study emphasized the benefits of adjuvant PARP inhibitors for BRCA1/2 carriers. Additionally, a HER3-DXd study hinted at innovative therapies for high-risk patients.

1 of 1

Story summary

At SABCS 2024, Dr. Avan J. Armaghani unveiled promising advancements in treating hormone receptor-positive, HER2-negative metastatic breast cancer. The EMBER-3 study showcased the powerful combination of imlunestrant and abemaciclib, while the OlympiA study emphasized the benefits of adjuvant PARP inhibitors for BRCA1/2 carriers. Additionally, a HER3-DXd study hinted at innovative therapies for high-risk patients.